{
    "nct_id": "NCT04648202",
    "official_title": "A Phase 1/1b Open-Label Study to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination With Pembrolizumab, in Subjects With Advanced Malignancies",
    "inclusion_criteria": "* Measurable disease\n* Eastern Cooperative Oncology Group Performance Status 0-1.\n* Highly effective contraception if risk of conception exists\n* A female subject is eligible if not pregnant, not breastfeeding, not a woman of childbearing potential (WOCBP) or is a WOCBP that uses highly effective contraception\n* Subjects with HIV who are healthy and how a low risk of acquired immunodeficiency syndrome related outcomes\n* For combination part: Subjects must have histologically confirmed locally advanced, unresectable or metastatic solid tumours where there is regulatory approval for use of pembrolizumab as a monotherapy agent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior systemic anticancer therapy within 28 days or 5- half-lives, whichever is shorter, before the first dose of study drug.\n* Prior therapy with any OX40 agonist, CD137 (4-1BB) agonist, CD40 agonist, GITR, or CD27 targeting therapy (single agent or combination).\n* Prior radiotherapy within 2 weeks of start of study treatment.\n* HIV infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.\n* Uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis, primary CNS tumours, or solid tumours with CNS metastases as the only measurable disease.\n* Prior history of any grade ≥3 immune-related AE (irAE) that has not improved to grade ≤1; any grade ≥3 irAE that resulted in discontinuation of treatment, significant (grade ≥3 NCI CTCAE Version 5.0) treatment-related cytokine release syndrome.\n* Use of immunosuppressive agents, hypersensitivity or intolerance to monoclonal antibodies or their excipients, persistent grade ≥1 NCI CTCAE Version 5 toxicity related to prior therapy or any condition that would significantly impair and/or prohibit the participant's participation in the study, as per the investigator's judgement.\n* Vaccination with a live vaccine within 30 days before first dose of study drug.\n* Participants with a known additional malignancy that is progressing or has required active treatment in the past 3 years.\n* Participants with severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.",
    "miscellaneous_criteria": ""
}